IMMUNITYBIO, INC. financials

IBRX CIK 0001326110

Source: EDGAR filings · Built 2026-06-02T03:16:40Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -308.81M -398.19M -397.42M -415.73M -307.98M -173.39M
EBITDA -240.50M -326.63M -343.74M -333.04M -316.04M -208.14M
Working Capital 253.12M 129.64M 235.80M -360.28M -34.65M 43.58M
Net Debt -45.32M -99.89M 356.75M 619.27M -141.02M -19.60M
Gross Margin 99.34% 100.00% 100.00% 100.00%
Operating Margin -226.00% -2334.23% -58239.55% -146374.17% -35361.88% -36509.09%
Net Margin -310.18% -2804.77% -93761.41% -173569.58% -37129.55% -36669.59%
Return on Equity (ROE) 70.21% 84.56% 99.35% 93.12% 143.20% 185.17%
Return on Assets (ROA) -70.01% -108.00% -115.61% -114.96% -73.96% -100.21%
Current Ratio 5.10× 3.36× 5.05× 0.28× 0.91× 1.64×
Debt-to-Equity -0.09× -0.09× -1.06× -1.62× -0.17× -0.13×
Effective Tax Rate 0.04% 0.00% 0.01% -0.01% -0.00% 0.82%
Cash Conversion Ratio 0.87× 0.95× 0.63× 0.81× 0.79× 0.77×
Accruals Ratio -0.09× -0.06× -0.43× -0.22× -0.15× -0.23×
SBC % of Revenue 32.49% 233.52% 7904.02% 16741.25% 6122.16% 361.49%
CapEx Coverage -78.71× -56.28× -11.96× -4.31× -8.18× -102.89×
Free Cash Flow Per Share $-0.34 $-0.57 $-0.78 $-1.04 $-0.79 $-0.46

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 17.68× 148.08× 5414.40× 8905.65× 2589.73× 8421.99×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 113.29M 14.74M 622.00K 240.00K
Revenues 113.29M 14.74M 622.00K 240.00K 934.00K 605.00K
Cost of Goods and Services Sold 753.00K 0 0 0
Research and Development Expense 190.14M 232.37M 248.15M 195.96M 139.51M
Selling, General and Administrative Expense 168.78M 129.62M 102.71M 135.26M 71.32M
Operating Expenses 358.93M 362.87M 351.54M 331.21M 221.49M
Operating Income (Loss) -256.03M -344.18M -362.25M -351.30M -330.28M -220.88M
Income Tax Expense (Benefit) -135.00K 0 -40.00K 34.00K 9.00K -1.85M
Net Income (Loss) Attributable to Parent -351.40M -413.56M -583.20M -416.57M -346.79M -221.85M
Earnings Per Share, Basic $-0.38 $-0.59 $-1.15 $-1.04 $-0.89 $-0.59
Weighted Average Number of Shares Outstanding, Basic 919.86M 697.31M 508.64M 399.90M 389.23M 377.07M
Earnings Per Share, Diluted $-0.38 $-0.62 $-1.15 $-1.04 $-0.89 $-0.59
Weighted Average Number of Shares Outstanding, Diluted 919.86M 700.44M 508.64M 399.90M 389.23M 377.07M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 88.33M 143.43M 265.45M 104.64M 181.10M 34.91M
Assets, Current 314.88M 184.59M 294.08M 140.58M 334.35M 111.71M
Assets 501.90M 382.93M 504.45M 362.36M 468.91M 221.38M
Liabilities, Current 61.75M 54.94M 58.28M 500.86M 369.00M 68.13M
Liabilities 1.00B 871.06M 1.09B 812.18M 712.82M 339.87M
Stockholders' Equity Attributable to Parent -500.47M -489.10M -586.99M -447.33M -242.17M -119.81M
Common Stock, Shares, Outstanding 1.01B 852.90M 670.87M 421.57M 397.83M 382.24M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -304.94M -391.24M -366.76M -337.51M -274.42M -171.72M
Payments to Acquire Property, Plant, and Equipment 3.85M 6.89M 30.58M 78.16M 33.56M 1.67M
Net Cash Provided by (Used in) Investing Activities -149.80M -12.25M -30.47M 27.30M -84.89M -19.81M
Payments for Repurchase of Common Stock 0 0
Net Cash Provided by (Used in) Financing Activities 400.24M 281.63M 558.34M 233.61M 505.44M 150.68M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (IBRX CIK 0001326110), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

HY

HYSTER-YALE, INC.

RPC

Ridgepost Capital, Inc.

BBAI

BigBear.ai Holdings, Inc.